Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

Autor: Evan Popoff, Michael L. Andria, Yingxin Xu, Sam Keeping, Chrysalyne D. Schmults, Amarnath Challapalli, Gerasimos Konidaris, Chieh-I Chen, Matthew G. Fury, Andreas Kuznik, Kanwarjit Singh, Rachel Allen, Thi-Minh-Thao Huynh, Morganna Freeman, Medha Sasane, Eggert Stockfleth, Dieter Ayers, Ali Mojebi, Shannon Cope
Rok vydání: 2020
Předmět:
Zdroj: Future oncology (London, England). 17(5)
ISSN: 1744-8301
Popis: Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. Patients & methods: We performed an indirect treatment comparison of cemiplimab and other available systemic therapies for patients with advanced cutaneous squamous cell carcinoma. Results: Cemiplimab was associated with benefits in OS (hazard ratios range: 0.07–0.52) and progression-free survival (hazard ratios range: 0.30–0.67) versus EGFR inhibitors and pembrolizumab (data from KEYNOTE-629). Cemiplimab was more efficacious versus platinum-based chemotherapy in terms of OS. Conclusion: Cemiplimab may offer improvements in survival for advanced cutaneous squamous cell carcinoma patients compared with existing systemic therapies.
Databáze: OpenAIRE